Sunifiram: The Complete Supplement Guide

Quick Reference Card

Overview / What Is Sunifiram?

The Basics

Sunifiram is an experimental compound that has generated interest in the nootropics community for its potential to sharpen focus, improve memory, and enhance mental clarity. First created in the year 2000 by researchers at the University of Florence in Italy, it was developed as part of ongoing work to find more potent alternatives to piracetam, one of the original "smart drugs."

Despite being related to the racetam family, sunifiram is technically not a racetam. Its chemical structure breaks from the classic pyrrolidone backbone found in piracetam, placing it in its own category as a piperazine-derived compound. What makes it noteworthy is its reported potency: animal studies suggest its anti-amnesiac effects are roughly 1,000 times stronger than piracetam on a per-weight basis.

It is critical to understand that sunifiram remains an experimental compound. As of 2026, it has never been tested in human clinical trials, has never undergone formal safety testing, and is not approved for use as a drug or dietary supplement anywhere in the world. All efficacy data comes from animal studies, primarily in mice and rats.

The Science

Sunifiram (DM-235) is a synthetic piperazine-derived compound first synthesized by Gualtieri and colleagues at the University of Florence as a molecular simplification of the diazabicyclononanone scaffold [1]. It was designated DM-235 during development and is structurally classified as 1-benzoyl-4-propanoylpiperazine (C14H18N2O2, MW 246.31 g/mol, CAS 314728-85-3).

Although derived from piracetam-related research, sunifiram does not retain the pyrrolidone ring that defines the racetam class. It is commonly categorized as an ampakine-like nootropic due to its downstream effects on AMPA receptor signaling, though direct AMPA receptor binding has not been demonstrated [5].

In preclinical models, sunifiram prevented scopolamine-induced amnesia at doses 1,000-fold lower than piracetam (effective at 0.001-0.1 mg/kg i.p. vs. 30-100 mg/kg for piracetam) in the mouse passive avoidance test [3]. It also reversed amnesia induced by mecamylamine, baclofen, and clonidine, suggesting activity across multiple neurotransmission systems [3].

Chemical & Nutritional Identity

Sunifiram is a fully synthetic compound with no natural dietary sources. It was developed through systematic molecular simplification of bicyclic nootropic scaffolds [1]. The compound features a piperazine core with benzoyl and propanoyl substituents. It is a white to off-white powder in its pure form.

Mechanism of Action

The Basics

Sunifiram's exact mechanism of action is not fully understood, but researchers have identified several key pathways through which it appears to work in animal studies.

Think of the brain's communication network like a series of switchboards. Each switchboard has different types of connections that handle different aspects of signaling. Sunifiram appears to interact primarily with a connection point called the glycine-binding site on NMDA receptors. These receptors are critical for learning and memory because they help strengthen the connections between brain cells, a process known as long-term potentiation, or LTP. Stronger connections mean better learning and recall.

When sunifiram activates this glycine site, it triggers a cascade of events inside the neuron. Two key enzymes, CaMKII and PKCa, become more active. These enzymes help reinforce the neural connections involved in forming and retaining memories. The end result is enhanced AMPA receptor function, which is why sunifiram is sometimes called an "ampakine," even though it does not directly bind to AMPA receptors.

Sunifiram also appears to increase the release of acetylcholine, a neurotransmitter involved in attention, focus, and memory. This may explain why some users report improved concentration alongside memory benefits.

The Science

The pharmacological profile of sunifiram involves multiple signaling pathways, with the primary mechanism centering on glycine-binding site modulation of NMDA receptors (NMDARs).

NMDAR Glycine Site Activation: In mouse hippocampal slices, sunifiram (10-100 nM) enhanced NMDAR-dependent long-term potentiation (LTP) in a bell-shaped dose-response curve peaking at 10 nM. This enhancement was blocked by 7-chloro-kynurenic acid (7-ClKN), a glycine-site antagonist, but not by ifenprodil (polyamine-site inhibitor), confirming specificity to the glycine-binding site [7].

CaMKII/PKCa Signaling Cascade: Sunifiram treatment increased phosphorylation of:

• AMPA receptor (GluR1 at Ser-831) via CaMKII activation
• NMDA receptor (NR1 at Ser-896) via PKCa activation
• Src family kinases (Tyr-416), upstream of PKCa

The LTP enhancement was significantly inhibited by PP2 (Src family inhibitor), establishing the pathway: glycine-site activation -> Src kinase -> PKCa -> CaMKII -> AMPAR phosphorylation -> enhanced LTP [7].

Acetylcholine Release: Sunifiram increases acetylcholine release from rat cerebral cortex in vitro [5]. This cholinergic enhancement may contribute to attention and memory effects independent of the glutamatergic pathway.

Receptor Binding Profile: Sunifiram showed no affinity at concentrations up to 1 uM for glutamate, GABA, serotonin, dopamine, adrenergic, histamine, acetylcholine, or opioid receptors. Testing on recombinant AMPA receptors showed no direct potentiation, indicating sunifiram is not an AMPA receptor positive allosteric modulator [6]. However, the AMPA antagonist NBQX blocked its antiamnesic effects, suggesting indirect downstream AMPA activation [2].

Glucose Transport: Sunifiram antagonizes barbiturate-induced inhibition of glucose transport in human erythrocytes in vitro (Ki = 26.0 uM), correlating with nootropic potency, though this is considered unlikely to be the primary mechanism.

Absorption & Bioavailability

The Basics

There is very limited data on how sunifiram is absorbed and processed by the human body because no formal pharmacokinetic studies have been conducted in humans.

What is known from animal studies and community reports is that sunifiram appears to be orally active at very low doses, suggesting reasonable absorption through the digestive tract. Many users report feeling effects within 30-60 minutes of oral administration, with some noting faster onset when taken sublingually (under the tongue), which allows the compound to bypass the digestive system and enter the bloodstream more directly.

The effects of sunifiram are generally reported to last 1-3 hours, suggesting a relatively short half-life. This is consistent with its low molecular weight and simple chemical structure.

The Science

No formal pharmacokinetic studies have been published for sunifiram in humans or animals. The following observations are derived from preclinical efficacy data and community reports:

• Oral bioactivity: Demonstrated in mice at 0.01-0.1 mg/kg p.o. in the passive avoidance test [3], confirming oral absorption sufficient for CNS activity
• Onset of action: Preclinical protocols typically administered sunifiram 20 minutes before behavioral testing [3], suggesting rapid absorption
• Duration: Community reports consistently describe effects lasting 1-3 hours
• Sublingual administration: Reported by users to produce faster onset than oral; no formal comparative data exists
• Blood-brain barrier penetration: Confirmed indirectly by CNS effects in behavioral and electrophysiological studies. ADMET modeling of sunifiram-carbamate hybrids suggests the parent scaffold is blood-brain barrier permeable [11]

Formal pharmacokinetic parameters (Cmax, Tmax, AUC, half-life, volume of distribution, protein binding, metabolism, elimination route) have not been characterized for sunifiram. This section requires additional research data.

Research & Clinical Evidence

The Basics

All research on sunifiram has been conducted in animals, primarily mice and rats. No human clinical trials have ever been completed. While the animal results are promising for cognitive enhancement, it is important to understand that animal studies do not always translate to human outcomes.

The key findings from animal research include:

Memory protection: Sunifiram prevented memory loss caused by drugs that impair different brain signaling systems. In both mice (passive avoidance test) and rats (Morris water maze), sunifiram protected against chemically-induced amnesia at remarkably low doses.

Alzheimer's disease model: In mice with olfactory bulb removal (a model that mimics some aspects of Alzheimer's disease), daily sunifiram treatment for 7-12 days improved spatial memory and object recognition. Notably, it did not improve depressive symptoms in the same model.

Brain cell communication: In brain tissue samples, sunifiram strengthened the connections between neurons, a process critical for learning. This effect peaked at very low concentrations and followed a bell-shaped curve, meaning more is not necessarily better.

The Science

Anti-amnesiac Activity (Mouse, Passive Avoidance):
Sunifiram prevented scopolamine-induced amnesia at 0.001-0.1 mg/kg i.p. and 0.01-0.1 mg/kg p.o., comparable in efficacy to piracetam (30-100 mg/kg i.p.), aniracetam (100 mg/kg p.o.), and rolipram (30 mg/kg p.o.) but at doses 1,000-fold lower. Additionally prevented amnesia induced by mecamylamine (20 mg/kg), baclofen (2 mg/kg), and clonidine (0.125 mg/kg) [3].

Spatial Memory (Rat, Morris Water Maze):
Sunifiram (0.1 mg/kg i.p., 20 min pre-training) prevented scopolamine-induced (0.8 mg/kg) impairment in both acquisition and retention/retraining phases [3].

Olfactory Bulbectomy Model (Mouse, Alzheimer's-like):
OBX mice treated with sunifiram (0.01-1.0 mg/kg p.o.) daily for 7-12 days showed significant improvement in:

• Y-maze spatial reference memory
• Novel object recognition (short-term memory)
• Hippocampal LTP restoration

Effects were blocked by gavestinel (glycine-site inhibitor), confirming NMDAR-dependent mechanism. Sunifiram did not ameliorate depressive behaviors (tail suspension test) [8].

Hippocampal LTP Enhancement (Mouse, In Vitro):
In hippocampal slices, sunifiram at 10-100 nM enhanced LTP with bell-shaped dose-response peaking at 10 nM. Enhancement mediated through glycine-site of NMDAR -> PKCa/Src -> CaMKII -> AMPAR phosphorylation cascade [7].

Motor and Safety Profile (Mouse):
At highest effective antiamnesic doses, sunifiram did not impair motor coordination (rota-rod test) or modify spontaneous motility and inspection activity (Animex and hole board tests). Sunifiram reduced pentobarbitone-induced hypnosis duration without modifying induction time [3].

No Human Clinical Trials: As of 2026, no registered clinical trials for sunifiram exist on ClinicalTrials.gov. No formal toxicology studies have been published [6].

Evidence & Effectiveness Matrix

Scoring note: Evidence Strength scores are constrained by the absence of any human clinical data. All efficacy evidence comes from rodent behavioral studies and in vitro hippocampal slice preparations. Reported Effectiveness scores are from community sentiment analysis (Tier 3 sources only, no Tier 2 structured review platforms).

Benefits & Potential Effects

The Basics

Based on animal research and community reports, sunifiram's primary potential benefits center on cognitive enhancement:

Cognitive clarity and focus are the most consistently reported benefits. Users describe an ability to concentrate more intensely and think more clearly, often comparing the experience to the clarity provided by prescription focus medications but without the same stimulant side effects. However, these are anecdotal reports, and no controlled human studies exist to confirm them.

Memory improvement is supported by animal research showing sunifiram can prevent and reverse chemically-induced memory impairment. Some users report improved recall and information retention, though isolating this effect from other supplements in a stack is difficult.

Mood elevation is reported by many community members, with descriptions of increased happiness, optimism, and a "sunny" mental state. However, this must be balanced against equally frequent reports of irritability and mood instability, particularly at higher doses.

It is essential to remember that these potential benefits are based on animal studies and uncontrolled self-reports. Without human clinical trials, the actual benefit profile in humans remains uncharacterized.

The Science

Preclinical evidence supports the following benefit categories:

Anti-amnesiac activity: The most robust evidence. Sunifiram prevents amnesia across multiple pharmacological models (scopolamine, mecamylamine, baclofen, clonidine) at 0.001-0.1 mg/kg, suggesting broad-spectrum memory protection independent of any single neurotransmitter system [3] [5].

LTP enhancement: Sunifiram potentiates hippocampal LTP at nanomolar concentrations (10 nM optimal), a cellular mechanism widely associated with learning and memory formation [7].

Cholinergic enhancement: Increased acetylcholine release from cerebral cortex may support attention and cognitive processing [5].

Potency advantage: Four orders of magnitude more potent than piracetam on anti-amnesiac endpoints, allowing effective cognitive enhancement at milligram-scale doses [5].

When you're taking multiple supplements, it's hard to know which one is doing the heavy lifting. The benefits described above may overlap with effects from other items in your stack, lifestyle changes, or seasonal variation. Doserly helps you untangle that by keeping everything in one place, with timestamps, doses, and outcomes logged together.

Over time, this builds something more valuable than any product review: your personal evidence record. You can see exactly when you started this supplement, what else was in your routine at the time, and how your tracked health markers responded. That clarity makes the difference between guessing and knowing, whether you're talking to a healthcare provider or simply deciding if it's worth reordering.

[!CTA Track Your Stack|/download|b|health-profile]

Side Effects & Safety Considerations

The Basics

Sunifiram has never undergone formal safety testing in humans, which means the side effect profile is based entirely on animal studies and community self-reports. This is a significant limitation.

Commonly reported side effects from community users include:

• Headaches, particularly when taken without a choline source or in combination with stimulants
• Irritability and mood changes, including anger and snapping at people, reported by multiple independent users
• Heart palpitations, especially at higher doses or combined with caffeine/stimulants
• Overstimulation, described as uncomfortable intensity, restlessness, or anxiety-like sensations
• Brain fog at high doses, paradoxically the opposite of the intended effect

Serious safety concerns:

• At least one hospitalization has been reported in the community, involving high-dose sunifiram combined with caffeine
• Reports of manic episodes, with "confidence bordering on mania" described by some users
• Rapid tolerance development, leading some users to escalate doses into potentially dangerous ranges
• No known long-term safety data exists

Populations that should avoid sunifiram:

• Anyone with heart conditions (palpitations reported)
• Individuals taking stimulant medications
• Pregnant or breastfeeding individuals (no safety data)
• Anyone not comfortable using an unregulated experimental compound

The Science

Preclinical safety data (limited):
At the highest effective antiamnesic doses, sunifiram did not impair motor coordination (rota-rod test), spontaneous motility, or inspection activity in mice [3]. No formal LD50, subchronic, chronic, genotoxicity, or reproductive toxicity studies have been published.

Community-reported adverse effects:

• Irritability and emotional dysregulation: Multiple independent reports across r/Nootropics threads spanning 2013-2025. Appears dose-related but present even at moderate doses for some individuals.
• Cardiovascular: Heart palpitations and heartbeat irregularities reported at doses above 10-20mg, especially in combination with stimulants.
• Manic symptoms: Euphoria progressing to mania reported in several community accounts. At least one hospitalization involving high-dose sunifiram + caffeine combination.
• Rapid tolerance: Multiple users report diminishing effects within days of regular use, with one user escalating from 10mg to 60mg over one week.
• Potential BZP metabolism: One community discussion raised the concern that sunifiram may be metabolized into benzylpiperazine (BZP), a recreational stimulant. This has not been confirmed or refuted by published research.

Drug interaction risk: Community reports indicate sunifiram potentiates stimulants (caffeine, modafinil, nicotine) and cholinergic compounds (noopept), potentially to dangerous levels. The AMPA/NMDA-enhancing mechanism provides a plausible pharmacological basis for synergistic overstimulation with glutamatergic and cholinergic agents.

Dosing & Usage Protocols

The Basics

There is no established human dose for sunifiram because no clinical trials have been conducted. The doses discussed here are extrapolated from animal studies and community self-experimentation. Use this information with extreme caution.

Commonly reported dosing range: 5-10 mg per dose, taken orally or sublingually. This range is based on allometric scaling from effective rodent doses (1 mg/kg in mice and rats, which translates to approximately 0.08-0.16 mg/kg in humans) and is consistent with the most positive community reports.

Important dosing considerations:

• Start at the lowest possible dose (5 mg or less) to assess individual response
• A precision milligram scale is strongly recommended due to the compound's extreme potency
• Sublingual administration reportedly produces faster onset than oral
• Most experienced users advise against daily use; 2-3 times per week with breaks is commonly recommended to prevent tolerance
• Do not combine with stimulants, especially caffeine, modafinil, or amphetamine-based medications
• Consider supplementing with a choline source (e.g., Alpha-GPC, phosphatidylcholine) to reduce the risk of headaches

The Science

Animal dosing data:

• Passive avoidance test (mouse): Effective at 0.001-0.1 mg/kg i.p. and 0.01-0.1 mg/kg p.o. [3]
• Morris water maze (rat): 0.1 mg/kg i.p. [3]
• OBX model (mouse): 0.01-1.0 mg/kg p.o. daily for 7-12 days [8]
• Hippocampal LTP (mouse slice): Optimal at 10 nM, bell-shaped curve [7]

Allometric human dose extrapolation:
Based on 1 mg/kg effective in both mice and rats, interspecies scaling yields a preliminary human equivalent dose of 0.08-0.16 mg/kg, or approximately 5.4-11 mg for a 68 kg (150 lb) individual.

When your stack includes several supplements, each with its own dose, form, and timing requirements, the logistics alone can derail consistency. Doserly consolidates all of it into one protocol view, so every dose across your entire routine is accounted for without spreadsheets or guesswork.

The app also tracks cumulative intake for nutrients that appear in multiple products. If your multivitamin, standalone supplement, and fortified protein shake all contain the same nutrient, Doserly adds them up and shows you the total alongside recommended and upper limits. Managing a thoughtful supplement protocol shouldn't require a degree in nutrition science. The app handles the complexity so you can focus on staying consistent.

[!CTA Manage Your Doses|/download|b|dose-tracking]

What to Expect (Timeline)

Based entirely on community reports (no clinical timeline data exists):

First dose (0-3 hours):

• Onset within 30-60 minutes (faster with sublingual administration)
• Peak effects at 1-2 hours: heightened mental clarity, focus, potential mood elevation
• Some users report sensory enhancement (more vivid colors, music appreciation)
• Effects taper over 2-3 hours

First week (daily or near-daily use):

• Cognitive benefits may be most pronounced during this initial period
• Some users report diminishing returns within days, suggesting rapid tolerance development
• Side effects such as irritability, headaches, or overstimulation may emerge
• Most experienced users recommend not using daily to preserve effectiveness

Weeks 2-4 (if cycling):

• Users who cycle (2-3 times per week with breaks) report more sustainable benefits
• Those using daily often report the need to increase doses, which is not recommended
• Baseline cognition may show subtle improvement on non-dosing days according to some reports

Long-term (1+ months):

• Very limited long-term community data available
• No clinical data on long-term effects or safety
• Most regular users report maintaining a cycling protocol to manage tolerance

One of the hardest parts of any supplement routine is knowing whether it's working when results unfold gradually over weeks or months. Without a record, it's easy to abandon something too early or keep taking something that isn't delivering. Doserly solves that by giving you a visual timeline of your entire supplementation history mapped against the outcomes you care about.

When everything is in one view, you can compare how different supplements in your stack are performing over the same period. You can see whether adding this supplement coincided with the improvement you've noticed, or whether the timing points to something else entirely. That kind of clarity turns patience into a strategy rather than a gamble.

[!CTA See Your Trends|/download|b|health-profile]

Interactions & Compatibility

Synergistic

• Choline sources (Alpha-GPC, Phosphatidylcholine): Community reports suggest co-administration with choline may enhance effects and reduce headaches, consistent with sunifiram's cholinergic enhancement mechanism [5]
• L-Theanine: Recommended by community members to counteract overstimulation and promote calm focus
• Magnesium: Suggested to help modulate NMDA receptor activity and reduce excitotoxicity risk

Caution / Avoid

• Caffeine: Reports of dangerous overstimulation. At least one hospitalization reported from high-dose sunifiram + caffeine combination
• Modafinil / Armodafinil: One user reported "persistent headaches and odd cognitive effects that took months to go away" from this combination
• Noopept: Multiple reports of intensified and unpredictable effects when combined. One user described feeling "high out of my mind"
• Amphetamines / Stimulant medications: Pharmacological basis for synergistic excitotoxicity via enhanced glutamatergic signaling
• Nicotine: Community reports of feeling unwell when smoking on sunifiram, likely due to potentiation of cholinergic signaling
• Other ampakines or racetams: Potential for compounding glutamatergic effects

Condition Contraindications

• Cardiovascular conditions: Palpitations and heartbeat irregularities reported
• Seizure disorders: NMDA/AMPA-enhancing compounds may lower seizure threshold (theoretical concern)
• Psychiatric conditions: Manic episodes reported; individuals with bipolar disorder or psychotic disorders should avoid
• Pregnancy / Breastfeeding: No safety data; avoid

How to Take / Administration Guide

Oral administration:

• Measure dose precisely with a milligram scale (do not eyeball or use volumetric scoops without calibration)
• Can be taken with or without food (no formal data on food interactions)
• Swallow with water or place under tongue for sublingual absorption

Sublingual administration:

• Place measured powder under the tongue and hold for 30-60 seconds before swallowing
• Users report faster onset (15-30 minutes vs. 30-60 minutes oral)
• May produce stronger peak effects due to bypassing first-pass metabolism

Timing recommendations:

• Take in the morning or early afternoon to avoid potential sleep disruption
• Allow 9+ hours before intended bedtime
• Allow 20-30 minutes before tasks requiring enhanced focus

Cycling protocol (community-derived):

• Most experienced users recommend 2-3 doses per week maximum
• Take breaks of at least 1-2 weeks periodically to prevent tolerance accumulation
• Do not escalate doses in response to diminishing effects; instead, take a break

What to avoid:

• Do not combine with stimulants (caffeine, modafinil, amphetamines)
• Do not use daily for extended periods
• Do not take doses above 10 mg without significant prior experience
• Do not use without a precision milligram scale

Choosing a Quality Product

Sunifiram is not sold as a mainstream dietary supplement. It is available through specialized nootropic and research chemical vendors. This creates significant quality concerns:

Quality verification challenges:

• No USP, NSF, or ConsumerLab testing programs cover sunifiram
• No GMP-certified facilities specifically validated for sunifiram production
• Product purity and identity can vary significantly between vendors
• One community member reported zero effects from one vendor but strong effects from another, highlighting potential quality inconsistency

What to look for:

• Certificate of Analysis (CoA): Request third-party analytical testing results showing identity confirmation (HPLC, NMR, or mass spectrometry) and purity percentage
• Vendor reputation: Research vendor reviews in nootropic communities (r/Nootropics, LongeCity forums)
• Appearance: Pure sunifiram powder should be white to slightly off-white
• Proper labeling: Product should be clearly labeled with the compound name, weight, and batch number

Red flags:

• Vendors selling sunifiram as a "dietary supplement" (it is not classified as one)
• No CoA available upon request
• Significantly below-market pricing
• Pre-mixed with other compounds without clear labeling
• Health or therapeutic claims on packaging

Sunifiram is sold as a research chemical, not as a dietary supplement. Product quality, purity, and safety are not guaranteed by any regulatory framework. Use at your own risk.

Storage & Handling

• Temperature: Store at room temperature (59-77 F / 15-25 C)
• Light sensitivity: Keep away from direct sunlight; store in an opaque or amber container
• Moisture sensitivity: Store in an airtight container with desiccant if possible; sunifiram powder is hygroscopic
• Shelf life: Approximately two years when stored properly in cool, dry, dark conditions
• Travel: Transport in original sealed container; keep away from heat sources
• Signs of degradation: Discoloration (yellowing), clumping, change in odor, or change in potency may indicate degradation
• Handling: Use a precision milligram scale. Avoid handling with wet or oily hands. Clean measuring equipment between uses.

Lifestyle & Supporting Factors

Sunifiram targets cognitive function. The following lifestyle factors may complement or influence its effects:

Sleep: Adequate sleep (7-9 hours) is foundational for the memory consolidation processes that sunifiram aims to enhance. Using sunifiram to compensate for chronic sleep deprivation is counterproductive. One community user reported maintained performance during sleep deprivation, but this should not be considered a sustainable strategy.

Choline intake: Sunifiram increases acetylcholine release, which may increase choline demand. Dietary choline sources (eggs, liver, fish) or supplemental choline (Alpha-GPC, CDP-Choline) may support optimal response and reduce headache risk.

Stress management: Chronic stress impairs the hippocampal LTP processes that sunifiram enhances. Stress reduction practices (meditation, exercise, nature exposure) may improve the compound's efficacy.

Exercise: Regular aerobic exercise independently enhances BDNF expression and hippocampal neurogenesis, potentially complementing sunifiram's LTP-enhancing effects.

Caffeine consideration: While caffeine is a common cognitive enhancer, community reports indicate it should be used cautiously or avoided with sunifiram due to potential overstimulation.

Monitoring: Because no clinical safety data exists, users should pay close attention to cardiovascular symptoms (heart rate, palpitations), mood changes (irritability, mania), and cognitive effects (paradoxical brain fog). Discontinue use if concerning symptoms arise.

Regulatory Status & Standards

United States:
Sunifiram is classified as an unapproved "New Drug" under 21 U.S.C. section 321(p)(1). Its use in dietary supplements, food, or medicine is unlawful. However, it is not a scheduled/controlled substance, meaning possession for personal research purposes is not explicitly prohibited. The FDA has registered sunifiram in its Global Substance Registration System (GSRS) with UNII 66924E735K, but this does not imply regulatory review or approval [10].

International:

• No country has approved sunifiram for therapeutic use as of 2026
• Not listed in EU EFSA approved health claims or novel food databases
• Not found in Health Canada Natural Health Product or TGA Australia databases

Athlete considerations:
Sunifiram is not specifically named on the WADA 2026 Prohibited List. However, category S0 ("Non-Approved Substances") prohibits "any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use." Sunifiram clearly falls within this category. Athletes subject to WADA, USADA, or other anti-doping testing should consider sunifiram prohibited and avoid it entirely.

• No NSF Certified for Sport or Informed Sport certification exists for sunifiram products
• No GlobalDRO entry for sunifiram
• Not found on the Cologne List

Athletes subject to anti-doping regulations should treat sunifiram as a prohibited substance under WADA category S0 (Non-Approved Substances). There is no certified-for-sport version of this compound.

Frequently Asked Questions

Is sunifiram safe?
There is no definitive answer. Sunifiram has never undergone human clinical trials or formal toxicology testing. Animal studies suggest a low toxicity profile at effective doses, but this does not guarantee human safety. Community reports include both positive experiences and concerning side effects including irritability, heart palpitations, and manic episodes.

Is sunifiram legal?
In the US, sunifiram is classified as an unapproved new drug. It is not a controlled/scheduled substance, but its use in dietary supplements, food, or medicine is unlawful. It is generally sold as a "research chemical." Regulatory status varies by country.

How does sunifiram compare to piracetam?
Sunifiram is structurally derived from piracetam research but is not technically a racetam. Animal studies suggest it is approximately 1,000 times more potent than piracetam for anti-amnesiac effects, meaning effective doses are in milligrams rather than grams. However, piracetam has decades of human use data and clinical trials, while sunifiram has none.

Can I take sunifiram every day?
Most experienced community members advise against daily use due to rapid tolerance development. A cycling protocol of 2-3 times per week with periodic breaks is commonly recommended.

Should I take sunifiram with a choline supplement?
Community reports suggest that co-supplementation with a choline source (Alpha-GPC, phosphatidylcholine) may enhance effects and reduce the risk of headaches. This is consistent with sunifiram's mechanism of increasing acetylcholine release.

How does sunifiram compare to unifiram?
Sunifiram (DM-235) and unifiram (DM-232) are closely related compounds from the same research program. Community reports suggest unifiram may produce clearer focus with longer duration (3-4 hours vs. 1-2 hours), while sunifiram may have more pronounced memory and mood effects. Both lack human clinical data.

Can sunifiram be detected on a drug test?
Standard workplace drug panels do not test for sunifiram. However, athletes subject to WADA/USADA testing should consider it prohibited under category S0 (Non-Approved Substances).

Myth vs. Fact

Myth: "Sunifiram is just a stronger version of piracetam."
Fact: While sunifiram was derived from piracetam-related research, it is not structurally a racetam (it lacks the pyrrolidone ring). Its mechanism of action centers on the glycine-binding site of NMDA receptors, which is distinct from piracetam's proposed mechanisms. The "stronger piracetam" label is an oversimplification [5].

Myth: "Sunifiram is an AMPA receptor agonist."
Fact: Testing on recombinant AMPA receptors showed no direct potentiation by sunifiram. It is better described as producing downstream AMPA receptor activation indirectly through NMDA glycine-site stimulation and subsequent CaMKII/PKCa signaling cascades. The "ampakine" label is based on functional effects, not direct receptor binding [6] [7].

Myth: "Sunifiram is safe because animal studies show no toxicity."
Fact: No formal toxicology studies have been published for sunifiram. The absence of toxicity in limited behavioral studies in mice does not constitute a safety profile. As of 2026, sunifiram has never undergone the standard battery of safety testing (LD50, subchronic, chronic, genotoxicity, reproductive toxicity, carcinogenicity) required for drug or supplement approval [6].

Myth: "Higher doses of sunifiram produce better cognitive effects."
Fact: Hippocampal LTP studies show sunifiram's enhancement follows a bell-shaped dose-response curve, peaking at 10 nM. Higher concentrations showed diminishing effects. Community reports mirror this, with users frequently reporting that doses above 10-20 mg produce brain fog, overstimulation, and unpleasant side effects rather than enhanced cognition [7].

Myth: "Sunifiram is a dietary supplement."
Fact: Sunifiram is classified in the US as an unapproved new drug. It is not a dietary supplement, vitamin, mineral, herb, or amino acid. Its sale and marketing as a dietary supplement is unlawful under US law.

Sources & References

Mechanistic Studies

[1] Manetti D, Ghelardini C, Bartolini A, et al. "Molecular simplification of 1,4-diazabicyclo[4.3.0]nonan-9-ones gives piperazine derivatives that maintain high nootropic activity." J Med Chem. 2000;43(23):4499-4507. PMID: 11087574.

[2] Galeotti N, Ghelardini C, Pittaluga A, et al. "AMPA-receptor activation is involved in the antiamnesic effect of DM232 (unifiram) and DM235 (sunifiram)." Naunyn-Schmiedeberg's Arch Pharmacol. 2003;368:538-545.

Behavioral / Preclinical Studies

[3] Ghelardini C, Galeotti N, Gualtieri F, et al. "DM235 (sunifiram): a novel nootropic with potential as a cognitive enhancer." Naunyn-Schmiedeberg's Arch Pharmacol. 2002;365(6):419-426. PMID: 12070754. https://pubmed.ncbi.nlm.nih.gov/12070754/

[4] Scapecchi S, Martini E, Manetti D, et al. "Structure-activity relationship studies on unifiram (DM232) and sunifiram (DM235), two novel and potent cognition enhancing drugs." Bioorg Med Chem. 2004;12:71-85. PMID: 14697772.

Reviews & Pharmacological Characterization

[5] Romanelli MN, Galeotti N, Ghelardini C, Manetti D, Martini E, Gualtieri F. "Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers." CNS Drug Reviews. 2006;12(1):39-52. PMC: 6741768. PMID: 16834757. https://pmc.ncbi.nlm.nih.gov/articles/PMC6741768/

[6] Gualtieri F. "Unifi nootropics from the lab to the web: a story of academic (and industrial) shortcomings." J Enzyme Inhib Med Chem. 2016;31(2):187-194. PMID: 25831025.

Electrophysiological Studies

[7] Moriguchi S, Tanaka T, Narahashi T, Fukunaga K. "Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor." Hippocampus. 2013;23(10):942-951. PMID: 23733502. https://pubmed.ncbi.nlm.nih.gov/23733502/

[8] Moriguchi S, Tanaka T, Tagashira H, Narahashi T, Fukunaga K. "Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice." Behav Brain Res. 2013;242:150-157. PMID: 23295391. https://pubmed.ncbi.nlm.nih.gov/23295391/

Chemical Identity

[9] PubChem. "Sunifiram - Compound Summary." PubChem CID 4223812. https://pubchem.ncbi.nlm.nih.gov/compound/4223812

[10] FDA Global Substance Registration System. UNII: 66924E735K. https://precision.fda.gov/uniisearch/srs/unii/66924E735K

Derivative Research

[11] Agha KA, Abo-Dya NE, et al. "Novel Sunifiram-carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist." J Enzyme Inhib Med Chem. 2022;37(1):1241-1250. PMC: 9067966. PMID: 35484855.

Related Supplement Guides

Nootropic Compounds

• Alpha-GPC — Choline source commonly stacked with sunifiram
• Aniracetam — Racetam nootropic from the same research lineage

Related Compounds

• Piracetam — Parent scaffold inspiration for sunifiram development
• Unifiram (DM-232) — Closely related piperazine nootropic from the same research program
• Noopept — Peptide-derived nootropic frequently discussed alongside sunifiram
• Nefiracetam — Racetam-family nootropic with overlapping mechanism research